NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Want to cut your energy bills? Here’s how five experts are doing it 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
PHOENIX, May 31, 2017 -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Saeed Motahari, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the following healthcare conferences in June:
| Conference: | Jefferies 2017 Global Healthcare Conference | |||
| Date: | Thursday, June 8, 2017 | |||
| Time: | 11:00 a.m. Eastern Daylight Time | |||
| Location: | Grand Hyatt New York | |||
| Webcast: | http://wsw.com/webcast/jeff105/insy | |||
| Conference: | The JMP Securities Life Sciences Conference | |||
| Date: | Wednesday, June 21, 2017 | |||
| Time: | 12:30 p.m. Eastern Daylight Time | |||
| Panel Discussion: | Opioids | |||
| Location: | The St. Regis New York | |||
| Webcast: | Please note that JMP Securities will not webcast panel discussions. |
The Jefferies presentation will be webcast live at the aforementioned time as well as archived for 90 days thereafter, via the Company’s website at www.insysrx.com, under the Investors Section.
About INSYS
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets one product, SUBSYS® (fentanyl sublingual spray), CII, and has received approval for the marketing of SYNDROS™ (dronabinol) oral solution, CII, a proprietary, orally administered liquid formulation of dronabinol that INSYS believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.
Contact: Lisa M. Wilson T: 212-452-2793 E: [email protected]
